Tag : ASPIRIN

CONFERENCE UPDATE

Clopidogrel outperforms aspirin in reducing thrombotic and bleeding risk in chronic maintenance phase post-PCI with DES: 10-year HOST-EXAM findings
The 10-year follow-up of the HOST-EXAM trial showed that clopidogrel monotherapy was superior to aspirin in reducing POCO, thrombotic events, and bleeding risk in patients after PCI with DES. These long-term findings support clopidogrel as a preferred antiplatelet monotherapy strategy during the chronic maintenance phase post-PCI with DES.
CONFERENCE UPDATE

Long-term clopidogrel monotherapy superior to aspirin in high ischemic risk patients post-PCI: Results from the SMART-CHOICE 3 trial
The SMART-CHOICE 3 trial reveals that long-term clopidogrel monotherapy significantly reduces the risk of major adverse cardiac and cerebrovascular events compared to aspirin in high-risk patients following percutaneous coronary intervention (PCI), suggesting clopidogrel may be a superior treatment option for this population.
CONFERENCE UPDATE

Ticagrelor alone after drug-eluting coronary stenting halves major bleeding risks in PCI patients regardless of ACS status